Management of CCF

← Back to Index (💗 Cardiology)

Core Management Principles

Management of CCF utilizes a structured, four-pronged approach targeting inadequate cardiac output.

Reduce cardiac work.
Augment myocardial contractility.
Improve cardiac performance via preload and afterload reduction.
Identify and correct underlying structural or metabolic causes.

General Supportive Care

Environmental and Postural Interventions

Restrict physical activities to lower metabolic demand.
Treat exacerbating triggers including fever, obesity, and systemic infections.
Correct anemia via packed red blood cell transfusion (10-20 mL/kg). Administer intravenous furosemide prior to transfusion.
Nurse neonates in incubators with minimal handling.
Maintain neutral thermal environment (36-37°C) minimizing caloric and circulatory expenditure.
Prop infants at a 30° incline to pool edema fluid in dependent areas and reduce respiratory work.
Provide 40-50% humidified oxygen for isolated pulmonary congestion.
Avoid indiscriminate oxygen supplementation in left-to-right shunt lesions. Oxygen acts as a pulmonary vasodilator, inappropriately increasing pulmonary flow and worsening systemic hypoperfusion.
Employ cautious sedation in highly restless or dyspneic patients.

Nutritional and Fluid Management

Implement high-calorie feeding to counteract excessive metabolic demands and profound failure to thrive.
Fortify formula caloric density. Limit fortification >24 kcal/oz if diarrhea or renal solute load issues manifest.
Utilize continuous nocturnal nasogastric (NG) drip feeding. Overcomes extreme feeding fatigue, rapid respirations, and reduces gastroesophageal reflux.
Prefer human breast milk as ideal low-sodium nutritional source.
Avoid routine low-sodium infant formulas. Poorly tolerated and exacerbates diuretic-induced hyponatremia.
Older children require general heart-healthy diets (low fat, low sugar).

Pharmacological Management

Preload Reduction (Diuretics)

Reduce circulating blood volume, relieve pulmonary edema, and lower ventricular filling pressures.

Class	Agent	Mechanism/Clinical Notes	Dosage
Loop Diuretics	Furosemide	Inhibits Na/Cl reabsorption in loop of Henle. Rapid onset (20 min PO). Risk of contraction alkalosis, K+ depletion. Synergistic with ACE inhibitors.	IV: 1-2 mg/kg/dose. PO: 1-4 mg/kg/day divided 1-4 times.
Loop Diuretics	Bumetanide	Potent loop diuretic alternative.	IV/PO: 0.01-0.1 mg/kg/dose.
Thiazides	Chlorothiazide	Inhibits electrolyte reabsorption in distal tubule. Less potent than furosemide.	PO: 20-40 mg/kg/day divided twice or thrice.
Aldosterone Antagonists	Spironolactone	Promotes natriuresis and potassium retention. Blunts adverse cardiac fibrosis/remodeling.	PO: 1-3 mg/kg/day divided twice or thrice.

Afterload Reduction (Vasodilators)

Inhibit inappropriate compensatory renin-angiotensin-aldosterone system (RAAS) activation. Reduces systemic vascular resistance, thereby decreasing ventricular afterload.

Class	Agent	Mechanism/Clinical Notes	Dosage
ACE Inhibitors	Captopril	Blocks Angiotensin II production. Causes arterial/venous dilation. Monitor for acute kidney injury, dry cough, hypotension. Avoid in dehydration/neonates.	PO: 0.1-0.5 mg/kg/dose (Children).
ACE Inhibitors	Enalapril	Long-acting alternative to Captopril.	PO: 0.08-0.5 mg/kg/day divided q12-24h.
ARBs	Losartan	Utilized if ACE inhibitors induce persistent cough.	Titrate per clinical response.
ARNi	Sacubitril/Valsartan	Neprilysin inhibitor combined with ARB. Approved for >1 year age with systemic left ventricular systolic dysfunction (EF <=40%).	Dose depends on age/weight.
Direct Vasodilators	Sodium Nitroprusside	Acute care veno-arterial dilation.	IV: 0.5-8 µg/kg/min.

Myocardial Contractility Augmentation (Inotropes)

Indicated for severe decompensation, low-output states, or cardiogenic shock.

Class	Agent	Mechanism/Clinical Notes	Dosage
Cardiac Glycoside	Digoxin	Inhibits Na-K ATPase. Increases intracellular Ca2+. Enhances contractility, enhances vagal tone, lowers heart rate. Synergistic with ACEi.	PO Load: 25-60 µg/kg total. PO Maint: 2.5-15 µg/kg/day.
PDE-3 Inhibitor	Milrinone	Inodilator. Inhibits cAMP degradation. Increases contractility and causes peripheral vasodilation. Treats refractory low cardiac output.	IV: 0.25-1.0 µg/kg/min. Load 50 µg/kg.
Calcium Sensitizer	Levosimendan	Increases myocardial contractility without elevating intracellular calcium or oxygen demand.	IV Load: 6-12 µg/kg over 10 min. Maint: 0.05-0.2 µg/kg/min.
Catecholamines	Dobutamine / Dopamine	Acute ICU use. Increases cAMP via beta-adrenergic stimulation. Dopamine <5 µg causes renal vasodilation/natriuresis.	IV: 2-20 µg/kg/min.

Beta-Adrenergic Blockers

Counteract chronic maladaptive catecholamine surges.
Improve symptoms and induce reverse remodeling in stable, chronic CCF.
Contraindicated during acute decompensation requiring intravenous inotropes.
Carvedilol: Non-selective alpha/beta blocker with free-radical scavenging properties. Preferred agent. Start low dose (0.08-0.4 mg/kg/day) and titrate slowly (max 1.0 mg/kg/day).
Metoprolol: Selective beta-1 adrenergic receptor antagonist.

Novel Therapeutics

Ivabradine: Selectively inhibits the I_f ("funny") current in the sinoatrial node. Lowers resting heart rate without depressing myocardial contractility.
SGLT2 Inhibitors (e.g., Dapagliflozin, Empagliflozin): Block proximal tubule glucose reabsorption. Induce profound natriuresis/glucosuria. Emerging role in refractory HFpEF/HFrEF.

Acute Heart Failure: Hemodynamic Profiling

Rapidly categorize acute CCF presentations by evaluating venous congestion ("wet" vs "dry") and systemic perfusion ("cold" vs "warm") to guide targeted interventions.

Profile	Clinical Status	Immediate Management Strategy	Prognosis
Warm-Dry	Adequate perfusion, no congestion.	Optimize chronic oral medications.	Lowest mortality.
Warm-Wet	Adequate perfusion, significant congestion.	Administer diuretics. Titrate cautiously to avoid precipitating low output.	Favorable trajectory.
Cold-Dry	Poor perfusion, no congestion.	Avoid diuretics. Trial careful volume expansion.	High risk.
Cold-Wet	Poor perfusion, severe congestion.	Highest mortality risk. Early initiation of IV inotropes. Evaluate rapidly for mechanical circulatory support.	Threefold higher mortality.

Correcting Underlying Causes

Medical management acts as temporary stabilization for surgically amenable lesions.
Definitive cure requires rapid identification and correction of structural pathology.
Provide prostaglandin E1 infusion (0.05-0.1 µg/kg/min) for ductal-dependent lesions (e.g., coarctation, HLHS).
Treat tachycardia-induced cardiomyopathy with cardioversion or antiarrhythmics.
Correct severe hypocalcemia, hypoglycemia, or upper airway obstructions immediately.
Perform surgical anomalous left coronary artery (ALCAPA) reimplantation to halt irreversible myocardial ischemia.

Advanced Interventions and Surgical Care

Electrophysiology Interventions

Implantable Cardioverter-Defibrillator (ICD): Indicated for survivors of cardiac arrest or primary prevention in high-risk dilated/hypertrophic cardiomyopathy phenotypes.
Cardiac Resynchronization Therapy (CRT): Biventricular pacing. Corrects pacing-related dyssynchrony to improve functional status and reduce CCF admissions.

Mechanical Circulatory Support (MCS) & Transplantation

Extracorporeal Membrane Oxygenation (ECMO): Temporary stabilizing measure for refractory cardiogenic shock. High morbidity demands time-limited trials with distinct end-points.
Ventricular Assist Devices (VAD): Short or long-term mechanical support (e.g., Berlin Heart EXCOR). Utilized as a bridge to myocardial recovery or orthotopic heart transplantation.
Orthotopic Heart Transplantation: Definitive standard of care for end-stage CCF (Stage D) or severe Stage C CCF associated with life-threatening arrhythmias, severe growth failure, or refractory symptomatology not amenable to conventional surgical repair.